Abstract:MicroRNAs (miRNAs) control cell cycle progression by targeting the transcripts encoding for cyclins, CDKs and CDK inhibitors, such as p27KIP1 (p27). p27 expression is controlled by multiple transcriptional and posttranscriptional mechanisms, including translational inhibition by miR-221/222 and posttranslational regulation by the SCFSKP2 complex. The oncosuppressor activity of miR-340 has been recently characterized in breast, colorectal and osteosarcoma tumor cells. However, the mechanisms underlying miR-340-induced cell growth arrest have not been elucidated. Here, we describe miR-340 as a novel tumor suppressor in non-small cell lung cancer (NSCLC). Starting from the observation that the growth-inhibitory and proapoptotic effects of miR-340 correlate with the accumulation of p27 in lung adenocarcinoma and glioblastoma cells, we have analyzed the functional relationship between miR-340 and p27 expression. miR-340 targets three key negative regulators of p27. The miR-340-mediated inhibition of both Pumilio family RNA-binding proteins (PUM1 and PUM2), required for the miR-221/222 interaction with the p27 3′-UTR, antagonizes the miRNA-dependent downregulation of p27. At the same time, miR-340 induces the stabilization of p27 by targeting SKP2, the key posttranslational regulator of p27. Therefore, miR-340 controls p27 at both translational and posttranslational levels. Accordingly, the inhibition of either PUM1 or SKP2 partially recapitulates the miR-340 effect on cell proliferation and apoptosis. In addition to the effect on tumor cell proliferation, miR-340 also inhibits intercellular adhesion and motility in lung cancer cells. These changes correlate with the miR-340-mediated inhibition of previously validated (MET and ROCK1) and potentially novel (RHOA and CDH1) miR-340 target transcripts. Finally, we show that in a small cohort of NSCLC patients (n=23), representative of all four stages of lung cancer, miR-340 expression inversely correlates with clinical staging, thus suggesting that miR-340 downregulation contributes to the disease progression.

Mir-1470 Mediates Lapatinib Induced P27 Upregulation By Targeting C-Jun

Mir-221 Confers Lapatinib Resistance by Negatively Regulating P27kip1 in HER2-positive Breast Cancer.

Mir-145-5p Inhibits Epithelial-Mesenchymal Transition Via the JNK Signaling Pathway by Targeting MAP3K1 in Non-Small Cell Lung Cancer Cells.

Mir-486 Promotes Capan-2 Pancreatic Cancer Cell Proliferation by Targeting Phosphatase and Tensin Homolog Deleted on Chromosome 10 (PTEN)

miR‐221 confers lapatinib resistance by negatively regulating p27 kip1 in HER2‐positive breast cancer

Mir-19B-3p Promotes Human Pancreatic Cancer Capan-2 Cells Proliferation by Targeting Phosphatase and Tension Homolog

Microrna-187 Inhibits Pten Expression And Promotes Cell Proliferation In Non-Small-Cell Lung Cancer

Mir-433 Inhibits Breast Cancer Cell Growth Via the MAPK Signaling Pathway by Targeting Rap1a

Upregulation of MiR-196a Promotes Cell Proliferation by Downregulating P27kip1 in Laryngeal Cancer

Mir‐137 Targets Cdc42 Expression, Induces Cell Cycle G1 Arrest and Inhibits Invasion in Colorectal Cancer Cells

Mir-143-3p Targeting LIM Domain Kinase 1 Suppresses the Progression of Triple-Negative Breast Cancer Cells.

Mirna-24-3p Promotes Cell Proliferation and Inhibits Apoptosis in Human Breast Cancer by Targeting P27kip1.

Mir-150, P53 Protein And Relevant Mirnas Consist Of A Regulatory Network In Nsclc Tumorigenesis

Mir-135b, Upregulated in Breast Cancer, Promotes Cell Growth and Disrupts the Cell Cycle by Regulating Lats2

Down-Regulation of Mir-4500 Promoted Non-Small Cell Lung Cancer Growth

Mir-145 Suppresses the Proliferation, Invasion and Migration of NSCLC Cells by Regulating the BAX/BCL-2 Ratio and the Caspase-3 Cascade

MiR-519d-3p Suppresses Breast Cancer Cell Growth and Motility Via Targeting LIM Domain Kinase 1

Mir-493 by Regulating of C-Jun Targets Wnt5a/PD-L1-inducing Esophageal Cancer Cell Development

Lysophosphatidic acid receptor 6 regulated by miR-27a-3p attenuates tumor proliferation in breast cancer

MiR-27b suppresses epithelial–mesenchymal transition and chemoresistance in lung cancer by targeting Snail1

miR-340 inhibits tumor cell proliferation and induces apoptosis by targeting multiple negative regulators of p27 in non-small cell lung cancer